Cargando…

Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to united states food and drug administration (FDA) guidelines

PURPOSE: Myocardial late gadolinium enhancement was originally validated using higher than label-recommended doses of gadolinium chelate. The objective of this study was to evaluate available evidence for various gadolinium dosing regimens used for CMR. The relationship of gadolinium dose warnings (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nacif, Marcelo S, Arai, Andrew E, Lima, Joao AC, Bluemke, David A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305456/ https://www.ncbi.nlm.nih.gov/pubmed/22376193 http://dx.doi.org/10.1186/1532-429X-14-18

Ejemplares similares

Gadolinium-enhanced cardiac magnetic resonance imaging: administered dose in relationship to United States Food and Drug Administration (FDA) guidelines
por: Nacif, Marcelo, et al.
Publicado: (2012)

Myocardial tissue tagging with cardiovascular magnetic resonance
por: Shehata, Monda L, et al.
Publicado: (2009)

Quantification of myocardial scar assessed by late gadolinium enhancement CMR in the multi-ethnics study of atherosclerosis: comparisons of 7 different methods
por: Rizzi, Patricia B, et al.
Publicado: (2013)

The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance
por: Noureldin, Radwa A, et al.
Publicado: (2012)

Submillimeter diffusion tensor imaging and late gadolinium enhancement cardiovascular magnetic resonance of chronic myocardial infarction
por: Pashakhanloo, Farhad, et al.
Publicado: (2017)

Cardiovascular magnetic resonance in an adult human population: serial observations from the multi-ethnic study of atherosclerosis
por: Yoneyama, Kihei, et al.
Publicado: (2017)

Society for Cardiovascular Magnetic Resonance guidelines for reporting cardiovascular magnetic resonance examinations
por: Hundley, W Gregory, et al.
Publicado: (2009)

Three-Dimensional Volumetric Assessment of Diastolic Function by Cardiac Magnetic Resonance Imaging: The Multi-Ethnic Study of Atherosclerosis (MESA)
por: Nacif, Marcelo S, et al.
Publicado: (2017)

Cardiovascular Computed Tomography and Magnetic Resonance: History and Growing Impact in Brazil and in the World
por: Nacif, Marcelo Souto, et al.
Publicado: (2014)

Neurotoxic manifestations of high-dose intrathecal gadolinium administration for CT myelogram
por: Malalur, Pannaga, et al.
Publicado: (2020)

Society for Cardiovascular Magnetic Resonance (SCMR) guidelines for reporting cardiovascular magnetic resonance examinations
por: Hundley, W. Gregory, et al.
Publicado: (2022)

Myocardial late gadolinium enhancement cardiovascular magnetic resonance in patients with cirrhosis
por: Lossnitzer, Dirk, et al.
Publicado: (2010)

Dressler's syndrome demonstrated by late gadolinium enhancement cardiovascular magnetic resonance
por: Steadman, Christopher D, et al.
Publicado: (2009)

Accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis
por: Tzogias, Leonidas, et al.
Publicado: (2009)

Anomalous origin of left coronary artery diagnosed by magnetic resonance imaging
por: Falcão, Ricardo Oliveira, et al.
Publicado: (2010)

Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents
por: Lohrke, Jessica, et al.
Publicado: (2017)

Gadolinium retention and clearance after administration of macrocyclic magnetic resonance contrast agents to rats
por: Bussi, Simona, et al.
Publicado: (2019)

Cardiac resynchronization therapy guided by late gadolinium-enhancement cardiovascular magnetic resonance
por: Leyva, Francisco, et al.
Publicado: (2011)

Functionalization of gadolinium metallofullerenes for detecting atherosclerotic plaque lesions by cardiovascular magnetic resonance
por: Dellinger, Anthony, et al.
Publicado: (2013)

Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis
por: Fontana, Marianna, et al.
Publicado: (2015)

Information to Improve Public Perceptions of the Food and Drug Administration (FDA’s) Tobacco Regulatory Role
por: Osman, Amira, et al.
Publicado: (2018)

The Food and Drug Administration’s (FDA’s) Drug Safety Surveillance During the COVID-19 Pandemic
por: Diak, Ida-Lina, et al.
Publicado: (2022)

Trabeculated (non-compacted) and compact myocardium in adults: the multi-ethnic study of atherosclerosis
por: Kawel, Nadine, et al.
Publicado: (2012)

Diffuse myocardial fibrosis evaluation using cardiac magnetic resonance T1 mapping: sample size considerations for clinical trials
por: Liu, Songtao, et al.
Publicado: (2012)

Late gadolinium enhancement cardiovascular magnetic resonance in genotyped hypertrophic cardiomyopathy with normal phenotype
por: Strijack, Bradford, et al.
Publicado: (2008)

Recovery of methamphetamine associated cardiomyopathy predicted by late gadolinium enhanced cardiovascular magnetic resonance
por: Lopez, Javier E, et al.
Publicado: (2009)

Gadolinium in pediatric cardiovascular magnetic resonance: what we know and how we practice
por: Meng, Howard, et al.
Publicado: (2012)

Prognostic and functional implications of left atrial late gadolinium enhancement cardiovascular magnetic resonance
por: Quail, Michael, et al.
Publicado: (2019)

Split dose versus single bolus gadolinium administration in ecv calculation at 3 tesla cmr
por: McDiarmid, Adam K, et al.
Publicado: (2015)

Repeat and single dose administration of gadodiamide to rats to investigate concentration and location of gadolinium and the cell ultrastructure
por: Davies, Julie, et al.
Publicado: (2021)

Physician Awareness and Utilization of Food and Drug Administration (FDA)-Approved Labeling for Pharmacogenomic Testing Information
por: Stanek, Eric J., et al.
Publicado: (2013)

Comparison of gadolinium dose and acquisition time for late gadolinium enhancement at 3.0 T
por: Doltra, Adelina, et al.
Publicado: (2014)

Sample size calculation for clinical trials using cardiac magnetic resonance partition coefficient and extracellular volume fraction for the assessment of diffuse myocardial fibrosis
por: Liu, Songtao, et al.
Publicado: (2013)

Pulmonary distensibility and flow dynamics in systemic sclerosis using velocity encoded magnetic resonance imaging
por: Shehata, Monda L, et al.
Publicado: (2009)

Inter-study reproducibility of cardiovascular magnetic resonance tagging
por: Donekal, Sirisha, et al.
Publicado: (2013)

Toward Replacing Late Gadolinium Enhancement With Artificial Intelligence Virtual Native Enhancement for Gadolinium-Free Cardiovascular Magnetic Resonance Tissue Characterization in Hypertrophic Cardiomyopathy
por: Zhang, Qiang, et al.
Publicado: (2021)

Low prevalence of fibrosis in thalassemia major assessed by late gadolinium enhancement cardiovascular magnetic resonance
por: Kirk, Paul, et al.
Publicado: (2011)

Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension
por: Freed, Benjamin H, et al.
Publicado: (2012)

Late gadolinium enhancement by cardiovascular magnetic resonance provides prognostic information in symptomatic alcoholic cardiomyopathy
por: Xiangli, Wei
Publicado: (2015)

Gray blood late gadolinium enhancement cardiovascular magnetic resonance for improved detection of myocardial scar
por: Fahmy, Ahmed S., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9m1f4df60lobqh0nrhe42r2v63